T. Rowe Price Investment Management, Inc. Vaxcyte, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $158 Billion
- Q2 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Vaxcyte, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 4,022,589 shares of PCVX stock, worth $447 Million. This represents 0.19% of its overall portfolio holdings.
Number of Shares
4,022,589
Previous 3,552,967
13.22%
Holding current value
$447 Million
Previous $243 Million
25.15%
% of portfolio
0.19%
Previous 0.15%
Shares
7 transactions
Others Institutions Holding PCVX
# of Institutions
287Shares Held
110MCall Options Held
248KPut Options Held
109K-
Black Rock Inc. New York, NY9.94MShares$1.11 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.8MShares$1.09 Billion0.01% of portfolio
-
Janus Henderson Group PLC London, X08.87MShares$986 Million0.37% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.2MShares$913 Million9.34% of portfolio
-
Wellington Management Group LLP Boston, MA4.59MShares$511 Million0.06% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $6.6B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...